Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1987; 10:998-1006
© 1987 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hamm, C.
Right arrow Articles by Weber, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hamm, C.
Right arrow Articles by Weber, P.

Biochemical evidence of platelet activation in patients with persistent unstable angina

CW Hamm, RL Lorenz, W Bleifeld, W Kupper, W Wober, and PC Weber

Abteilung fur Kardiologie, Universitatskrankenhaus Eppendorf, Hamburg, West Germany.

Thromboxane released from activated platelets and prostacyclin of the vessel wall may act as potent antagonistic modulators of platelet aggregability and coronary vascular tone. Therefore, urinary excretion of their major metabolites, 2,3-dinor-thromboxane B2 and 2,3-dinor-6-ketoprostaglandin F1 alpha, was studied in 16 patients presenting with prolonged angina at rest. The 10 patients whose condition did not improve under vigorous antianginal treatment within 48 hours exhibited higher thromboxane metabolite excretion than did the 6 patients who responded to therapy (2,208 +/- 1,542 versus 609 +/- 312 ng/g creatinine; p less than 0.001). Elevated values were also found in four of eight patients with sustained postinfarction angina. Enhanced thromboxane metabolite excretion was frequently associated with angiographic evidence of thrombus formation. When nine patients were restudied in a stable phase after 11 +/- 5 months, thromboxane metabolite excretion was consistently normal or high normal. Excretion of prostacyclin metabolites was not depressed in any patient but correlated weakly with thromboxane (r = 0.41). Thus, enhanced thromboxane production as an index of platelet activation may identify patients with active thrombus formation who could benefit most from platelet inhibitory treatment.


This article has been cited by other articles:


Home page
CLIN APPL THROMB HEMOSTHome page
S. A. Mousa, W. P. Jeske, and J. Fareed
Antiplatelet Therapy Prasugrel: A Novel Platelet ADP P2Y12 Receptor Antagonist
Clinical and Applied Thrombosis/Hemostasis, April 1, 2010; 16(2): 170 - 176.
[Abstract] [PDF]


Home page
Physiol. Rev.Home page
D. J. Duncker and R. J. Bache
Regulation of Coronary Blood Flow During Exercise
Physiol Rev, July 1, 2008; 88(3): 1009 - 1086.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J.-M. Dogne, J. Hanson, X. de Leval, P. Kolh, V. Tchana-Sato, L. de Leval, S. Rolin, A. Ghuysen, P. Segers, B. Lambermont, et al.
Pharmacological Characterization of N-tert-Butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a Novel Thromboxane A2 Receptor Antagonist and Thromboxane Synthase Inhibitor in a Rat Model of Arterial Thrombosis and Its Effects on Bleeding Time
J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 498 - 505.
[Abstract] [Full Text] [PDF]


Home page
Eur J Cardiovasc NursHome page
S. Willoughby, A. Holmes, and J. Loscalzo
Platelets and Cardiovascular Disease
European Journal of Cardiovascular Nursing, December 1, 2002; 1(4): 273 - 288.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. A. Mousa, J. M. Bozarth, M. S. Forsythe, and A. Slee
Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: Role of plasma calcium levels
Cardiovasc Res, September 1, 2000; 47(4): 819 - 826.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. A. Mousa, S. Khurana, and M. S. Forsythe
Comparative In Vitro Efficacy of Different Platelet Glycoprotein IIb/IIIa Antagonists on Platelet-Mediated Clot Strength Induced by Tissue Factor With Use of Thromboelastography : Differentiation Among Glycoprotein IIb/IIIa Antagonists
Arterioscler Thromb Vasc Biol, April 1, 2000; 20(4): 1162 - 1167.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. Neufeld, U. Nowak-Gottl, and R. Junker
Citrate-Theophylline-Adenine-Dipyridamol Buffer Is Preferable to Citrate Buffer as an Anticoagulant for Flow Cytometric Measurement of Platelet Activation
Clin. Chem., November 1, 1999; 45(11): 2030 - 2033.
[Full Text] [PDF]


Home page
CirculationHome page
M. Gawaz, F.-J. Neumann, and A. Schomig
Evaluation of Platelet Membrane Glycoproteins in Coronary Artery Disease : Consequences for Diagnosis and Therapy
Circulation, January 12, 1999; 99(1): e1 - e11.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. M. Zaacks, P. R. Liebson, J. E. Calvin, J. E. Parrillo, and L. W. Klein
Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications?
J. Am. Coll. Cardiol., January 1, 1999; 33(1): 107 - 118.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. A. Mousa, J. M. Bozarth, W. Lorelli, M. S. Forsythe, M. J. M. C. Thoolen, A. M. Slee, T. M. Reilly, and P. A. Friedman
Antiplatelet Efficacy of XV459, A Novel Nonpeptide Platelet GPIIb/IIIa Antagonist: Comparative Platelet Binding Profiles with c7E3
J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1277 - 1284.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
R. A. Bednar, S. L. Gaul, T. G. Hamill, M. S. Egbertson, J. A. Shafer, G. D. Hartman, R. J. Gould, and B. Bednar
Identification of Low Molecular Weight GP IIb/IIIa Antagonists That Bind Preferentially to Activated Platelets
J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1317 - 1326.
[Abstract] [Full Text]


Home page
StrokeHome page
S. A. Mousa, D.-X. Mu, and B. R. Lucchesi
Prevention of Carotid Artery Thrombosis by Oral Platelet GPIIb/IIIa Antagonist in Dogs
Stroke, April 1, 1997; 28(4): 830 - 836.
[Abstract] [Full Text]


Home page
CirculationHome page
I. Ott, F.-J. Neumann, M. Gawaz, M. Schmitt, and A. Schomig
Increased Neutrophil-Platelet Adhesion in Patients With Unstable Angina
Circulation, September 15, 1996; 94(6): 1239 - 1246.
[Abstract] [Full Text]


Home page
CirculationHome page
S. A. Mousa, W. F. DeGrado, D.-X. Mu, R. P. Kapil, B. R. Lucchesi, and T. M. Reilly
Oral Antiplatelet, Antithrombotic Efficacy of DMP 728, a Novel Platelet GPIIb/IIIa Antagonist
Circulation, February 1, 1996; 93(3): 537 - 543.
[Abstract] [Full Text]


Home page
HypertensionHome page
S. E. Kjeldsen, A. B. Weder, B. Egan, R. Neubig, A. J. Zweifler, and S. Julius
Effect of Circulating Epinephrine on Platelet Function and Hematocrit
Hypertension, May 1, 1995; 25(5): 1096 - 1105.
[Abstract] [Full Text]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement